🩸 Potential new standard of care in newly diagnosed Multiple Myeloma ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients. 👨‍⚕️ C. Ola Landgren, MD, PhD 🔗 https://ow.ly/Cx2L50XNJ7S

Happy New Year from The ASCO Post!

🔬 TAP Highlight of 2025: Is this the end of cancer research as we know it? A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide. 🔗 https://ow.ly/IGA850XNJ41#CancerResearch—jeopardizing

#YearInReview: In matched-related donor stem cell transplantation, cyclophosphamide + calcineurin inhibition significantly improved GVHD- & relapse-free survival vs standard therapy—without added toxicity. From #EHA25 🔸 David Curtis, MBBS, PhD 🔗 https://ow.ly/ZfQ450XNJ1R

TAP Highlight of 2025 - Update in early HER2+ Breast Cancer: • Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47) • Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%) • Signals for fewer CNS events (DB05) 🔗 https://ow.ly/3BCO50XNIRO

🚨 ICYMI: NCCN early 2025 updates impacted practice across: • 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options • 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added • 🧬 mCRC: expanded IO + BRAF-targeted combos • 🩸 Myeloma: quadruplets gaining ground 🔗 https://ow.ly/1j7j50XNIzM

Wishing you a wonderful holiday season!

👉 Major takeaways from Treatment Advances in Malignant Hematology from NCCNhem25: • Immunotherapy-first strategies expanding • MRD driving treatment intensity • Biomarkers guiding frontline choices • Outpatient management of cellular therapies 🔗 https://ow.ly/bU3350XNIyw

Deb Schrag, MD, MPH, has been chosen as the American Society of Clinical Oncology President for 2027–2028 The new Board of Directors and Nominating Committee Members have also been chosen. They will start their terms after the 2026 ASCO Annual Meeting. 🔗https://ow.ly/8Ve050XNLay

🫂 When doctors are the family members, the words hit differently. Filipe Coutinho, MD, reflects on navigating cancer not as a clinician, but as a loved one, and how it reshaped his approach to care. ✍️ Filipe Coutinho, MD 🔗 https://ow.ly/iJBZ50XNhSz

🏥 Dana-Farber Cancer Institute's Neuro-Inclusive Oncology Care & Empowerment Program is rethinking #cancercare for patients with intellectual and developmental disabilities—prioritizing communication, sensory needs, and workforce training. ✍️ Melissa Levin, MSW, LICSW 🔗 https://ow.ly/yBzM50XNfIJ#cancercare

💡 For women with BRCA1/2 mutations facing surgical menopause: new prospective data suggest menopausal hormone therapy can be used without increasing #breastcancer risk. Joanne Kotsopoulos, PhD | #SABCS25 Learn more: https://ow.ly/Pcs250XKAqj#breastcancer

Routine liquid biopsy screening for multiple cancers could cut late-stage cancer diagnoses nearly in half, per new modeling data of 14 cancer types. Earlier detection may significantly improve outcomes and reduce disease burden. 🔷 Chhatwal et al https://ow.ly/IIKj50XA802

Catch up on all of the highlights from ESMO Congress 2025! Dive into the latest breakthroughs in oncology in this #ESMO25-focused supplement from The ASCO Post including updates across immunotherapy, targeted treatments, and biomarkers. 🔗 https://ow.ly/JWtN50XA8rm

🆕 American Cancer Society Cancer Action Network study shows patients with cancer increasingly turn to crowdfunding for expenses. Only 11.5% of campaigns meet their goals, revealing major gaps in affordability and financial assistance #CostsofCare 🔸Zhiyuan Zheng, PhD 🔗 https://ow.ly/GUXl50XA883

The November 25 issue of The ASCO Post features insights from ESMO 2025, ASTRO 2025, NCCNhem 2025; perspectives on the AI era changing health care, cancer survivor concerns of health care costs, and MORE. Read the full issue 👉 https://ascopost.com/issues/november-25-2025/

🔬New CAPS analysis: Mild dilation of the main pancreatic duct is an independent risk factor for progression to pancreatic cancer in high-risk individuals. Risk reached 16% at 5 yrs and 26% at 10 yrs. ✍️ Marcia Irene Canto, MD, MHS 🔗 https://ow.ly/RnRA50XukBo

🆕 DESTINY-Breast09 data in HER2+ mBC: • 44% reduced risk of progression/death • PFS: 40.7 mo • ORR: 85% T-DXd + pertuzumab may redefine first-line treatment, per Sara Tolaney et al 🔗 https://ow.ly/qu8q50XtBp7

BART trial ASTRO25: Adjuvant Radiation Therapy after cystectomy reduced locoregional recurrence in pts w/ high-risk muscle-invasive Bladder Cancer Modern IMRT to the pelvis safe after surgery—supports IO integration in trials 🔷 Presenter Vedang Murthy, MD 🔗 https://ow.ly/Qexr50XrI7o

The NCCN's Clinical Practice Guidelines in Oncology to be integrated into @openevidence.bsky.social's medical AI platform so clinicians can access trusted, evidence-based cancer care recommendations for decision-making support via natural language search. ➡️https://ow.ly/QqaK50Xr3w4

Pembrolizumab + weekly paclitaxel ± bevacizumab in pts with platinum-resistant ovarian cancer led to improved PFS, OS in overall, PD-L1 CPS ≥ 1 populations ovariancancer 🗣️From ESMO25 👩‍⚕️Presenter Nicoletta Colombo, MD, PhD; Discussant https://ow.ly/FgHC50XqFJc

The November 10 issue of The ASCO Post features insights from ESMO, ASTRO, and SOHO meetings; a Special Report on disaster impacts on patients & staff; perspectives on alcohol-associated cancer risks, and climate change & cancer development. Read full issue here: ascopost.com/issues/novem...

Zenocutuzumab-zbco led to responses in 37% of patients in a small cohort of patients with NRG1+ cholangiocarcinoma 🔹Clinical benefit rate 58%, median PFS of 9.2 months 🔹Presented at #Targets25 by Alison Schram, MD of @mskcancercenter.bsky.social ascopost.com/news/october...

A conversation with Ravi B. Parikh, MD, MPP, highlights how he has helped increase access to palliative care by integrating an algorithm into EHR to identify patients with cancer who could benefit Palliative care visits increased: 44% vs 8% in control group ascopost.com/issues/octob...

Living a Full Life: The ASCO Post spotlights the career of third-generation clinician Neelima Denduluri, MD, in conversation with @jameabraham.bsky.social. Dr. Denduluri has been a lifetime advocate for equity in medicine, breast cancer oncologist, ASCO mentor, & more. ascopost.com/issues/octob...

“Cancer is probably the most vulnerable field for fraudulent research” -Reese A.K. Richardson, PhD, of @kelloggschoolnu.bsky.social Richardson et al reported the amount of fraudulent scientific papers is doubling every 1.5 years due to paper mills, etc. ascopost.com/news/october...

President Joe Biden has completed his radiation therapy course for prostate cancer and rang a ceremonial bell to commemorate the milestone ascopost.com/news/october...

Obesity-related cancers on the rise in younger and older adults globally, with data from 42 countries Incidence rates rose for 6 of 13 cancer types; rates of endometrial cancer and kidney cancer rose most sharply From Amy Berrington de Gonzalez, DPhil @icr.ac.uk et al ascopost.com/news/october...

Only 45% of US counties have oncologists and retirement looms for many New data show number of US oncologists billing Medicare rose from 2014 to 2024, but oncologist density/100,000 adults decreased Corresponding author M. Kelsey Kirkwood, MPH @ascocancer.bsky.social ascopost.com/news/october...

FDA Approval: The @fda.gov has approved revumenib (Revuforj) for R/R acute myeloid leukemia with a susceptible NPM1 mutation in adult & pediatric patients ≥1yr without alternative treatment options Supportive data from AUGMENT-101 trial show CR+CRh rate of 23.1% ascopost.com/news/october...

When it comes to cancer survival, study by Tohmasi et al confirms ‘it’s never too late’ to quit smoking. 🚬 Benefits seen across all cancer types and stages, including late-stage cancer Expert commentary from James M. Davis, MD, of @dukecancer.bsky.social ascopost.com/news/october...

evERA study from ESMO 2025: Oral giredestrant + everolimus improved PFS vs SoC in metastatic ER+, HER2– breast cancer Risk of disease progression or death reduced by 63% in ESR1-mutant cohort, 44% in ITT cohort Presented by @elmayermd.bsky.social ascopost.com/news/october...

Meta analysis by Alessandro Di Federico, MD, et al: Dual CTLA-4 + PD-1/PD-L1 blockade in NSCLC yielded 5-year OS of 19.8% vs 16.3% with monotherapy Median OS was longer in patients with PD-L1 TPS <1% & STK11 mutations Corresponding author: Biagio Ricciuti, MD, PhD ascopost.com/news/october...

New study from @alliance-org.bsky.social and AML Cooperative Group asks: Are age-based treatment classifications outdated? 🔻 5yr OS by age: 73% (ages 18–24) to 21% (≥75) @akeisfeld.bsky.social suggests a shift toward biology-driven eligibility over age thresholds. ascopost.com/news/october...

In patients <50 undergoing colonoscopy, odds for early-onset colorectal cancer higher in those with rectal bleeding. "If you have a person below the screening age with rectal bleeding, you should seriously consider a colonoscopy.” - Sandra Kavalukas, MD, at #ACS25 ascopost.com/news/october...

FANSS study: low-dose CT screening feasible, valuable for lung cancer screening for Asian non-smoking women Supports expansion of guidelines to include high-risk populations Presenter: @elaineshummd.bsky.social Discussant: David R. Baldwin, MD ascopost.com/news/october...

A 313-SNP polygenic risk score (PRS313) may help predict future breast cancer in pts with DCIS or LCIS, from Jasmine Timbres @kingscollegelondon.bsky.social Higher PRS313 linked to higher contralateral risk (DCIS; HR = 1.3) & ipsilateral risk (LCIS; HR = 2.16) ascopost.com/news/october...

In older adults with early-stage cervical cancer, adherence to recommended surgery or radiation significantly improved survival. In @jamanetworkopen.com, Suk et al urge addressing barriers to adherence to reduce mortality in aging populations. ascopost.com/news/october...

Study of 9/11 WTC first responders shows risks of toxic particulates from environmental catastrophes: 6× higher leukemia risk in responders with clonal hematopoiesis But, targeting IL1RAP could reduce inflammation-driven disorders ascopost.com/news/october...

The @usfda.bsky.social has approved cemiplimab-rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma FDA approval based on findings from the C-POST study: Median DFS not reached vs 49.4 months w/ placebo (HR = 0.32; P < .0001) ascopost.com/news/october...

Patients with HER2+ mCRC receiving chemo + bevacizumab/anti-EGFR therapy face worse survival than pts with HER2– disease - HR for PFS = 1.31 (P = .02) - HR for OS = 1.37 (P = .01) Corresponding author: Chiara Cremolini, MD, PhD ascopost.com/news/october...

Cases of kidney cancer projected to double by 2050 globally due to modifiable risk factors. From Alexander Kutikov, MD, FACS, et al ascopost.com/news/october...

BART Trial Presented at the ASTRO Annual Meeting: Adjuvant RT after cystectomy + chemo in MIBC improves survival with no excess grade ≥3 toxicity One of the first large randomized trials to show meaningful pelvic relapse reductions, says Vedang Murthy, MD ascopost.com/news/septemb...

Phase II LUNAR Trial: PSMA-targeted radiopharmaceutical plus SBRT improved PFS in pts with oligometastatic prostate cancer (18 vs 7 mo), which helped to delay ADT by 24 months Presented by Amar U. Kishan, MD, at the ASTRO Annual Meeting @astro-org.bsky.social ascopost.com/news/septemb...

On Sept 29th, Anthony Letai, MD, PhD, was sworn in as the new Director of the National Cancer Institute (NCI). He is known for his venetoclax research, predictive biomarker development, and work in apoptosis. ascopost.com/news/septemb...

PRISM Trial: first large-scale randomized study of AI in breast cancer screening in the US 📏 Will evaluate effects on cancer detection, recall rates, & radiologist and patient trust 👩‍⚕️Co-PI: Joann Elmore, MD, MPH 🔗 ascopost.com/news/septemb...

Study suggests that dietary supplement nicotinamide associated with reduced risk of new skin cancer development. ✅ Greatest benefit seen when taken after first skin cancer From Kimberly Breglio, MD, PhD, et al ascopost.com/news/septemb...

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell RCC led to extended median PFS without compromising safety. The median systemic therapy–free survival was 34 months. Insights from Chad Tang, MD, et al here: ascopost.com/news/septemb...

In the latest issue of The ASCO Post, Stuart M. Lichtman, MD, explains how the new @jco-asco.bsky.social guidelines could improve clinical trial reporting and enhanced care for older patients with cancer. Read more here: ascopost.com/issues/septe...

The September 25 issue of The ASCO Post features insights from @iaslc.bsky.social's WCLC and ASCO 2025, perspectives on palliative care integration, geriatric inclusivity in cancer trial data, accelerated aging in childhood cancer survivors, and MORE Full issue here: ascopost.com/issues/septe...